Tissue Heart Valves are also known as the biosynthetic valves; these are harvested from the pig heart valves (porcine) or from the sac surrounding the heart of the cow (bovine). Certain tissue valves are mounted on the frame or stent while others are used directly (stentless).

The demand for tissue heart valves is primarily witnessing growth on account of the high prevalence of heart valve diseases such as aortic valve degeneration and aortic stenosis, increase in demand for minimally invasive procedures, technological advancements of the tissue heart valves and longer life expectancy of the geriatric population.

The high prevalence observed in case of heart valve diseases such as the aortic valve degeneration and the aortic stenosis tend to drive the tissue heart valves market. According to the researchers, the aortic stenosis tends to be the second most common valvular disease in United States. The disease is present in about 5% population at the age of 65 years, with an increasing prevalence along with advancing age. A meta-analysis done on predominantly older studies in Europe, the USA and Taiwan resulted a population prevalence of Aortic stenosis of 12.4% and 3.4% suffering from severe aortic stenosis in patients that are 75 years and older.

The aortic stenosis is a condition which is more prevalent in the elderly population According to a population-based study, the incidence of aortic stenosis was found to be 0.2% during the fifth decade of life and reached till 9.8% during the eighth decade of life. Due to the high prevalence observed for heart valve diseases, there will be an increase in the demand for tissue heart valves replacement, thereby driving the market for tissue heart valves.

According to the Centers for Disease Control and Prevention, 2019, almost 2.5% of the U.S. population has valvular heart disease, but it is more common in older adults. The rheumatic heart disease tends to affect most commonly the mitral valve or the aortic valve, however any valve can be affected and more than one valve can be involved. Approximately 25,000 deaths in the U.S., each year are due to heart valve disease from causes other than rheumatic disease. The bicuspid aortic valve happens in about 1% to 2% of the population and is mostly common amongst men. Due to the rise in the number of patients suffering from valvular diseases, the demand for tissue heart valve replacements will increase, thereby driving the tissue heart valve market.

In Tissue heart valves device type segment, the stentless segment is expected to achieve a larger market share during the forecast period. The stentless tissue valves tend to offer advantages over the stented tissue valves such as reduction in rate of thrombosis, more physiological flow pattern and a superior hemodynamics in comparison to the stented valves. The structure offered by the stentless valve prostheses is designed for achieving a more physiological flow pattern when compared with the stented valves.

Apart from this, in several studies it has been reported that the stentless valves allow an improved postoperative coronary flow when compared with the stented valves after valve replacement for aortic stenosis. Due to the several advantages that the stentless tissue valves have to offer over the stented tissue valves, their demand will surely experience a surge in the market, thereby leading to an increase in the market of stentless tissue heart valves.

It has also been observed that for the stentless aortic root bio-prosthesis, the full root versus sub-coronary implantation offered better early transvalvular gradients, effective orifice area and left ventricular mass regression as well as late freedom from structural valve deterioration in many retrospective studies. Patients suffering from aortic stenosis and other valvular diseases will be more inclined towards the stentless tissue heart valves in contrast to the stented heart tissue valves because of the various benefits offered by them, hence leading to a growth in the demand of stentless tissue heart valves market.

Among all the regions, North America is expected to account for the largest share in the tissue heart valves market. The increase in the prevalence of valvular heart diseases, favourable reimbursement scenario of tissue heart valves and the rising product approvals for tissue heart valves are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period. The rise in product approvals by Food and Drug Administration has also driven the tissue heart valves market in North America. For instance, on May 13, 2021, the FDA approved Edwards Lifesciences LLC Company’s Edwards SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Heart Valve System, for use when the mitral valve fails and the patient has a prosthetic ring implanted around the mitral valve in order to help keep the shape.

Some of the key market players operating in the Tissue Heart Valves market includes Abbott, Boston Scientific Corporation, CryoLife, Inc., Edward Lifesciences Corporation, Medtronic, Sorin Group (LivaNova PLC), Braile Biomédica and Labcor Laboratórios, Colibri Heart Valve, ON-X LIFE TECHNOLOGIES, INC., JenaValve Technology Inc., TTK Healthcare Limited, Comed BV, Meril Life Sciences Pvt. Ltd., Beijing Balance Medical Technology Co.,Ltd, Venus Medtech and others.